Fusion Antibodies plc (LON:FAB – Get Free Report) shares were down 2.4% during mid-day trading on Thursday . The company traded as low as GBX 3.90 ($0.05) and last traded at GBX 4.10 ($0.05). Approximately 457,418 shares were traded during mid-day trading, a decline of 59% from the average daily volume of 1,104,111 shares. The stock had previously closed at GBX 4.20 ($0.05).
Fusion Antibodies Trading Down 2.4 %
The company has a market capitalization of £3.91 million, a P/E ratio of -102.50 and a beta of 0.49. The company has a 50-day simple moving average of GBX 3.92 and a 200 day simple moving average of GBX 3.56. The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87.
Insider Transactions at Fusion Antibodies
In related news, insider Adrian Kinkaid purchased 83,728 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were bought at an average cost of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,359.70). In other news, insider Adrian Kinkaid acquired 83,728 shares of the stock in a transaction dated Wednesday, October 16th. The shares were acquired at an average cost of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,359.70). Also, insider Richard John Buick bought 94,825 shares of Fusion Antibodies stock in a transaction that occurred on Monday, September 9th. The stock was purchased at an average cost of GBX 3 ($0.04) per share, with a total value of £2,844.75 ($3,703.14). Over the last quarter, insiders have purchased 298,553 shares of company stock worth $979,387. Insiders own 11.39% of the company’s stock.
Fusion Antibodies Company Profile
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.
Recommended Stories
- Five stocks we like better than Fusion Antibodies
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Breakout Alert: Qualcomm Just Hit The Rally Button
- When to Sell a Stock for Profit or Loss
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Fusion Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
